Breaking News Instant updates and real-time market news.

LEE

Lee Enterprises

$1.15 /

+0.045 (+4.09%)

07:09
06/18/20
06/18
07:09
06/18/20
07:09

Lee Enterprises reports Q2 EPS (9c) vs. (5c) last year

Reports Q2 revenue $121.37M vs. $122.7M last year. We are pleased to announce our solid second quarter financial results," said Kevin Mowbray, President and CEO. "Revenue and Adjusted EBITDA performance were strong, despite the immediate disruption in the last two weeks of the quarter due to the COVID-19 pandemic. Strong performance in our audience revenue and continued top line growth at TownNews, which have historically been stable revenue streams, drove results in the second quarter. Importantly, we closed on the transaction with Berkshire Hathaway, a strategic acquisition and financing that nearly doubled the size of our operations and eliminated our looming debt maturities, at highly attractive terms. The impact on our business from COVID-19 was significant and immediate. Our main priorities in the response to the pandemic were to ensure the safety and well-being of our employees, our advertisers and our consumers, while also continuing to deliver vital news and information to customers in our local markets. Our newsrooms play a crucial role in providing intensely local coverage of critical issues, and we are incredibly proud of our employees across the company during this challenging time. We took swift and decisive action in response to the headwinds. We immediately implemented both temporary and permanent cost actions, solidified our relationship with our local advertisers through a marketing grant program, enhanced our liquidity through the refinancing, and continued the acquisition integration. The combination of short-term and long-term actions taken now strengthens our local market position, and now more than ever, we believe that our compelling local content, strong audiences and audience engagement, and best-in-class operators, will allow us to emerge from this crisis stronger than ever."

  • 18

    Jun

TODAY'S FREE FLY STORIES

Recommendations
Ryder price target raised to $47 from $37 at Baird » 07:35
07/06/20
07/06
07:35
07/06/20
07:35
R

Ryder

$36.84 /

+0.53 (+1.46%)

Baird analyst Benjamin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
R Ryder
$36.84 /

+0.53 (+1.46%)

R Ryder
$36.84 /

+0.53 (+1.46%)

04/01/20 Mizuho
Bristol-Myers Squibb CVR price target raised to $6.17 from $4.52 at Mizuho
03/27/20 Wolfe Research
Ryder downgraded to Peer Perform from Outperform at Wolfe Research
03/23/20 SunTrust
SunTrust lowers price targets in Trucking and Logistics segment
03/10/20 Stifel
Ryder upgraded to Buy from Hold at Stifel
R Ryder
$36.84 /

+0.53 (+1.46%)

R Ryder
$36.84 /

+0.53 (+1.46%)

Hot Stocks
Apollo Global forms new origination platform » 07:35
07/06/20
07/06
07:35
07/06/20
07:35
APO

Apollo Global

$49.87 /

-0.34 (-0.68%)

Apollo Global announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
APO Apollo Global
$49.87 /

-0.34 (-0.68%)

APO Apollo Global
$49.87 /

-0.34 (-0.68%)

07/01/20 Barclays
Apollo Global price target raised to $51 from $44 at Barclays
06/30/20
Fly Intel: Top five analyst downgrades
06/30/20 Goldman Sachs
Apollo Global downgraded to Buy from Conviction Buy at Goldman Sachs
06/08/20 Citi
Citi downgrades Alternative Asset Managers to Market Weight, lowers four ratings
APO Apollo Global
$49.87 /

-0.34 (-0.68%)

  • 26
    Nov
APO Apollo Global
$49.87 /

-0.34 (-0.68%)

APO Apollo Global
$49.87 /

-0.34 (-0.68%)

APO Apollo Global
$49.87 /

-0.34 (-0.68%)

Hot Stocks
Bellus sinks 78% to $2.80 after Phase 2 chronic cough failure  07:33
07/06/20
07/06
07:33
07/06/20
07:33
BLU

Bellus Health

$12.01 /

+0.21 (+1.78%)

 
ShowHide Related Items >><<
BLU Bellus Health
$12.01 /

+0.21 (+1.78%)

BLU Bellus Health
$12.01 /

+0.21 (+1.78%)

06/26/20 H.C. Wainwright
Bellus Health initiated with a Buy at H.C. Wainwright
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
09/30/19
Fly Intel: Top five analyst initiations
09/30/19 Jefferies
Jefferies sees potential double in Bellus Health, starts shares at Buy
  • 05
    Sep
Hot Stocks
Abbott receives FDA approval for next-generation Gallant ICD, CRT-D devices » 07:32
07/06/20
07/06
07:32
07/06/20
07:32
ABT

Abbott

$92.25 /

+0.64 (+0.70%)

Abbott announced that the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ABT Abbott
$92.25 /

+0.64 (+0.70%)

ABT Abbott
$92.25 /

+0.64 (+0.70%)

07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
06/15/20 Piper Sandler
Abbott approval narrows competitive gap to DexCom, says Piper Sandler
06/11/20 UBS
Abbott's COVID-19 testing positive contributor, says UBS
06/09/20 Barrington
Surmodics price target raised to $62 from $56 at Barrington
ABT Abbott
$92.25 /

+0.64 (+0.70%)

ABT Abbott
$92.25 /

+0.64 (+0.70%)

ABT Abbott
$92.25 /

+0.64 (+0.70%)

ABT Abbott
$92.25 /

+0.64 (+0.70%)

Hot Stocks
ADC Therapeutics announces FDA lifts partial hold on camidanlumab tesirine trial » 07:32
07/06/20
07/06
07:32
07/06/20
07:32
ADCT

ADC Therapeutics

$52.61 /

+3.36 (+6.82%)

ADC Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ADCT ADC Therapeutics
$52.61 /

+3.36 (+6.82%)

ADCT ADC Therapeutics
$52.61 /

+3.36 (+6.82%)

06/09/20 Morgan Stanley
ADC Therapeutics initiated with an Overweight at Morgan Stanley
06/09/20 Cowen
ADC Therapeutics initiated with an Outperform at Cowen
06/09/20 BofA
ADC Therapeutics initiated with a Buy at BofA
06/09/20 BofA
ADC Therapeutics initiated with a Buy at BofA
  • 15
    May
  • 03
    Oct
Initiation
Venus Concept initiated with a Buy at BTIG » 07:32
07/06/20
07/06
07:32
07/06/20
07:32
VERO

Venus Concept

$3.53 /

+0.32 (+9.97%)

BTIG analyst Marie…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VERO Venus Concept
$3.53 /

+0.32 (+9.97%)

VERO Venus Concept
$3.53 /

+0.32 (+9.97%)

05:48 Today BTIG
Venus Concept initiated with a Buy at BTIG
03/31/20
Fly Intel: Top five analyst downgrades
03/31/20 Oppenheimer
Venus Concept downgraded to Perform at Oppenheimer as COVID-19 clouds outlook
03/31/20 Oppenheimer
Venus Concept downgraded to Perform from Outperform at Oppenheimer
VERO Venus Concept
$3.53 /

+0.32 (+9.97%)

VERO Venus Concept
$3.53 /

+0.32 (+9.97%)

Downgrade
Cooper Companies downgraded to Neutral, Baird see confluence of issues » 07:30
07/06/20
07/06
07:30
07/06/20
07:30
COO

Cooper Companies

$288.84 /

+1.505 (+0.52%)

, JNJ

Johnson & Johnson

$141.01 /

+0.755 (+0.54%)

As reported previously,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
COO Cooper Companies
$288.84 /

+1.505 (+0.52%)

JNJ Johnson & Johnson
$141.01 /

+0.755 (+0.54%)

COO Cooper Companies
$288.84 /

+1.505 (+0.52%)

05:19 Today Baird
Cooper Companies downgraded to Neutral from Outperform at Baird
06/05/20 UBS
UBS backs Buy on Alcon after Cooper results
05/26/20 Stephens
Cooper Companies price target raised to $325 from $300 at Stephens
05/26/20 KeyBanc
Cooper Companies price target lowered to $330 from $380 at KeyBanc
JNJ Johnson & Johnson
$141.01 /

+0.755 (+0.54%)

07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
COO Cooper Companies
$288.84 /

+1.505 (+0.52%)

JNJ Johnson & Johnson
$141.01 /

+0.755 (+0.54%)

JNJ Johnson & Johnson
$141.01 /

+0.755 (+0.54%)

COO Cooper Companies
$288.84 /

+1.505 (+0.52%)

JNJ Johnson & Johnson
$141.01 /

+0.755 (+0.54%)

JNJ Johnson & Johnson
$141.01 /

+0.755 (+0.54%)

Initiation
Vroom initiated with a Neutral at BofA » 07:27
07/06/20
07/06
07:27
07/06/20
07:27
VRM

Vroom

$54.21 /

+0.045 (+0.08%)

BofA analyst Nat…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VRM Vroom
$54.21 /

+0.045 (+0.08%)

07:13 Today Wedbush
Vroom initiated with an Outperform at Wedbush
06:41 Today Stifel
Stifel starts Vroom at Buy, sees premium as justified
06:40 Today JMP Securities
Vroom initiated with an Outperform at JMP Securities
06:19 Today Wells Fargo
Vroom initiated with an Overweight at Wells Fargo
  • 09
    Jun
VRM Vroom
$54.21 /

+0.045 (+0.08%)

VRM Vroom
$54.21 /

+0.045 (+0.08%)

Initiation
Everest Re initiated with a Buy at BofA » 07:25
07/06/20
07/06
07:25
07/06/20
07:25
RE

Everest Re

$200.50 /

-3.565 (-1.75%)

BofA analyst Joshua…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RE Everest Re
$200.50 /

-3.565 (-1.75%)

RE Everest Re
$200.50 /

-3.565 (-1.75%)

06:27 Today BofA
Everest Re initiated with a Buy at BofA
06/16/20 Wells Fargo
Wells Fargo upgrades Everest Re to Overweight on best market in 20 years
06/16/20 Wells Fargo
Everest Re upgraded to Overweight from Equal Weight at Wells Fargo
04/02/20 Keefe Bruyette
Everest Re upgraded to Outperform from Market Perform at Keefe Bruyette
RE Everest Re
$200.50 /

-3.565 (-1.75%)

RE Everest Re
$200.50 /

-3.565 (-1.75%)

Hot Stocks
Bellus Phase 2 chronic cough trial did not achieve statistical significance » 07:25
07/06/20
07/06
07:25
07/06/20
07:25
BLU

Bellus Health

$12.01 /

+0.21 (+1.78%)

Bellus Health announced…

Bellus Health announced topline results from its Phase 2 RELIEF trial of BLU-5937 in patients with refractory chronic cough. The trial did not achieve statistical significance for the primary endpoint of reduction in placebo-adjusted cough frequency at any dose tested, the company said. A clinically meaningful and highly statistically significant placebo-adjusted reduction in cough frequency was achieved in a pre-specified sub-group of high cough count patients, it added. BLU-5937 was also observed to be well tolerated with no serious adverse events reported and no withdrawals due to treatment-related adverse events at any dose, according to Bellus. "In the RELIEF trial, we observed data that we believe is competitive within the P2X3 class, including the reduction in cough frequency shown in patients with higher cough counts and a low taste effect. While we had hoped to see more response in the lower cough patients, BLU-5937 and other P2X3 antagonists may have the most benefit in patients with a greater disease burden," said Roberto Bellini, CEO of Bellus. "We believe the Phase 2 data support moving BLU-5937 forward into an adaptive Phase 2b trial enriched for higher cough count patients. We expect to begin this trial in the fourth quarter of 2020."

ShowHide Related Items >><<
BLU Bellus Health
$12.01 /

+0.21 (+1.78%)

BLU Bellus Health
$12.01 /

+0.21 (+1.78%)

06/26/20 H.C. Wainwright
Bellus Health initiated with a Buy at H.C. Wainwright
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
09/30/19
Fly Intel: Top five analyst initiations
09/30/19 Jefferies
Jefferies sees potential double in Bellus Health, starts shares at Buy
  • 05
    Sep
Downgrade
Healthcare Services downgraded to Hold from Buy at Benchmark » 07:21
07/06/20
07/06
07:21
07/06/20
07:21
HCSG

Healthcare Services

$24.29 /

-0.18 (-0.74%)

Benchmark analyst Bill…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HCSG Healthcare Services
$24.29 /

-0.18 (-0.74%)

HCSG Healthcare Services
$24.29 /

-0.18 (-0.74%)

04/22/20 Credit Suisse
Healthcare Services price target lowered to $27 from $32 at Credit Suisse
04/20/20 Baird
Healthcare Services upgraded to Outperform from Neutral at Baird
02/25/20 Northland
Healthcare Services initiated with an Outperform at Northland
02/12/20 Baird
Healthcare Services consensus estimates still too high, says Baird
HCSG Healthcare Services
$24.29 /

-0.18 (-0.74%)

HCSG Healthcare Services
$24.29 /

-0.18 (-0.74%)

Hot Stocks
Bellus Phase 2 trial of BLU-5937 did not achieve statistical significance  07:21
07/06/20
07/06
07:21
07/06/20
07:21
BLU

Bellus Health

$12.01 /

+0.21 (+1.78%)

 
ShowHide Related Items >><<
BLU Bellus Health
$12.01 /

+0.21 (+1.78%)

BLU Bellus Health
$12.01 /

+0.21 (+1.78%)

06/26/20 H.C. Wainwright
Bellus Health initiated with a Buy at H.C. Wainwright
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
09/30/19
Fly Intel: Top five analyst initiations
09/30/19 Jefferies
Jefferies sees potential double in Bellus Health, starts shares at Buy
  • 05
    Sep
Hot Stocks
ADMA Biologics commences operations at plasma collection facility, submits BLA » 07:20
07/06/20
07/06
07:20
07/06/20
07:20
ADMA

ADMA Biologics

$2.89 /

+0.03 (+1.05%)

ADMA Biologics announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ADMA ADMA Biologics
$2.89 /

+0.03 (+1.05%)

ADMA ADMA Biologics
$2.89 /

+0.03 (+1.05%)

05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
08/12/19 Dawson James
ADMA Biologics downgraded to Neutral from Buy at Dawson James
ADMA ADMA Biologics
$2.89 /

+0.03 (+1.05%)

  • 07
    Feb
Recommendations
Novocure has large growth opportunity in China, says Mizuho » 07:18
07/06/20
07/06
07:18
07/06/20
07:18
NVCR

Novocure

$60.64 /

+0.995 (+1.67%)

, ZLAB

Zai Lab

$81.16 /

+1.43 (+1.79%)

Mizuho analyst Difei Yang…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NVCR Novocure
$60.64 /

+0.995 (+1.67%)

ZLAB Zai Lab
$81.16 /

+1.43 (+1.79%)

NVCR Novocure
$60.64 /

+0.995 (+1.67%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
ZLAB Zai Lab
$81.16 /

+1.43 (+1.79%)

05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/27/20
Zai Lab initiated with a Buy at Goldman Sachs
04/16/20 Guggenheim
Guggenheim starts 'uniquely compelling' Zai Lab at Buy
NVCR Novocure
$60.64 /

+0.995 (+1.67%)

ZLAB Zai Lab
$81.16 /

+1.43 (+1.79%)

  • 23
    Jan
  • 01
    Aug
NVCR Novocure
$60.64 /

+0.995 (+1.67%)

Hot Stocks
Zealand Pharma announces opening of new Boston office » 07:17
07/06/20
07/06
07:17
07/06/20
07:17
ZEAL

Zealand Pharma

$35.53 /

+1.06 (+3.08%)

Pharma announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ZEAL Zealand Pharma
$35.53 /

+1.06 (+3.08%)

ZEAL Zealand Pharma
$35.53 /

+1.06 (+3.08%)

03/10/20 Morgan Stanley
Zealand Pharma EPS estimates cut at Morgan Stanley
11/19/19 Jefferies
Zealand Pharma downgraded to Hold from Buy at Jefferies
11/15/19 Needham
Zealand Pharma price target raised to $42 from $32 at Needham
10/15/19
Fly Intel: Top five analyst upgrades
ZEAL Zealand Pharma
$35.53 /

+1.06 (+3.08%)

Recommendations
Manhattan Associates price target raised to $105 from $83 at Benchmark » 07:17
07/06/20
07/06
07:17
07/06/20
07:17
MANH

Manhattan Associates

$92.81 /

+0.06 (+0.06%)

Benchmark analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MANH Manhattan Associates
$92.81 /

+0.06 (+0.06%)

MANH Manhattan Associates
$92.81 /

+0.06 (+0.06%)

05/28/20 SunTrust
Manhattan Associates price target raised to $98 from $80 at SunTrust
05/21/20 SunTrust
Manhattan Associates price target raised to $80 from $70 at SunTrust
05/21/20 Rosenblatt
Manhattan Associates price target raised to $100 from $80 at Rosenblatt
04/22/20 Benchmark
Manhattan Associates price target raised to $61 from $51 at Benchmark
MANH Manhattan Associates
$92.81 /

+0.06 (+0.06%)

MANH Manhattan Associates
$92.81 /

+0.06 (+0.06%)

Recommendations
Square price target raised to $150 from $83 at SunTrust » 07:16
07/06/20
07/06
07:16
07/06/20
07:16
SQ

Square

$113.30 /

-2.58 (-2.23%)

SunTrust analyst Andrew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SQ Square
$113.30 /

-2.58 (-2.23%)

SQ Square
$113.30 /

-2.58 (-2.23%)

07/01/20 MoffettNathanson
Square price target raised to $120 from $90 at MoffettNathanson
07/01/20 Rosenblatt
Square upgraded to Buy from Neutral at Rosenblatt
07/01/20 Rosenblatt
Square upgraded to Buy from Neutral at Rosenblatt
06/30/20
Fly Intel: Top five analyst initiations
SQ Square
$113.30 /

-2.58 (-2.23%)

SQ Square
$113.30 /

-2.58 (-2.23%)

SQ Square
$113.30 /

-2.58 (-2.23%)

SQ Square
$113.30 /

-2.58 (-2.23%)

Recommendations
LivePerson price target raised to $50 from $43 at Benchmark » 07:15
07/06/20
07/06
07:15
07/06/20
07:15
LPSN

LivePerson

$43.94 /

+0.9 (+2.09%)

Benchmark analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LPSN LivePerson
$43.94 /

+0.9 (+2.09%)

LPSN LivePerson
$43.94 /

+0.9 (+2.09%)

07/01/20 KeyBanc
LivePerson price target raised to $48 from $38 at KeyBanc
06/25/20 Northland
LivePerson conversation volume spike could prompt early renewals, says Northland
06/22/20 B. Riley FBR
LivePerson price target raised to $43 from $36 at B. Riley FBR
06/17/20 Northland
LivePerson price target raised to $45 from $40 at Northland
LPSN LivePerson
$43.94 /

+0.9 (+2.09%)

LPSN LivePerson
$43.94 /

+0.9 (+2.09%)

LPSN LivePerson
$43.94 /

+0.9 (+2.09%)

LPSN LivePerson
$43.94 /

+0.9 (+2.09%)

Hot Stocks
Myriad Genetics announces collaboration with OptraHealth for Gene ChatBOT » 07:15
07/06/20
07/06
07:15
07/06/20
07:15
MYGN

Myriad Genetics

$11.53 /

+0.275 (+2.44%)

Myriad Genetics announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MYGN Myriad Genetics
$11.53 /

+0.275 (+2.44%)

MYGN Myriad Genetics
$11.53 /

+0.275 (+2.44%)

06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
05/06/20 Piper Sandler
Myriad Genetics price target lowered to $14 from $20 at Piper Sandler
03/06/20 JPMorgan
Myriad Genetics price target lowered to $14 from $17 at JPMorgan
MYGN Myriad Genetics
$11.53 /

+0.275 (+2.44%)

MYGN Myriad Genetics
$11.53 /

+0.275 (+2.44%)

Hot Stocks
Avrobio doses new patients in Gaucher disease, cystinosis clinical trials » 07:14
07/06/20
07/06
07:14
07/06/20
07:14
AVRO

Avrobio

$17.79 /

-0.05 (-0.28%)

AVROBIO announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AVRO Avrobio
$17.79 /

-0.05 (-0.28%)

AVRO Avrobio
$17.79 /

-0.05 (-0.28%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
AVRO Avrobio
$17.79 /

-0.05 (-0.28%)

  • 13
    Feb
  • 17
    Jul
Downgrade
Veritone downgraded to Sell from Hold at Craig-Hallum » 07:14
07/06/20
07/06
07:14
07/06/20
07:14
VERI

Veritone

$15.63 /

-0.78 (-4.75%)

Craig-Hallum analyst Chad…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VERI Veritone
$15.63 /

-0.78 (-4.75%)

VERI Veritone
$15.63 /

-0.78 (-4.75%)

06/25/20 Roth Capital
Veritone price target raised to $18 from $7 at Roth Capital
11/08/19 JMP Securities
Veritone price target lowered to $7 from $10 at JMP Securities
11/07/19 Craig-Hallum
Veritone downgraded to Hold at Craig-Hallum after 'disapointing' Q3 results
11/07/19 Craig-Hallum
Veritone downgraded to Hold from Buy at Craig-Hallum
VERI Veritone
$15.63 /

-0.78 (-4.75%)

Initiation
Vroom initiated with an Outperform at Wedbush » 07:13
07/06/20
07/06
07:13
07/06/20
07:13
VRM

Vroom

$54.21 /

+0.045 (+0.08%)

Wedbush initiated…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VRM Vroom
$54.21 /

+0.045 (+0.08%)

06:41 Today Stifel
Stifel starts Vroom at Buy, sees premium as justified
06:40 Today JMP Securities
Vroom initiated with an Outperform at JMP Securities
06:19 Today Wells Fargo
Vroom initiated with an Overweight at Wells Fargo
04:48 Today Baird
Vroom initiated with an Outperform at Baird
  • 09
    Jun
VRM Vroom
$54.21 /

+0.045 (+0.08%)

VRM Vroom
$54.21 /

+0.045 (+0.08%)

Upgrade
Acasti Pharma upgraded to Buy from Neutral at B. Riley FBR » 07:12
07/06/20
07/06
07:12
07/06/20
07:12
ACST

Acasti Pharma

$0.53 /

+0.0158 (+3.05%)

B. Riley FBR analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ACST Acasti Pharma
$0.53 /

+0.0158 (+3.05%)

ACST Acasti Pharma
$0.53 /

+0.0158 (+3.05%)

02/18/20 H.C. Wainwright
Acasti Pharma price target lowered to $3 from $6 at H.C. Wainwright
01/13/20 Roth Capital
Amarin's Vascepa now the 'go-to' after competitor failures, says Roth Capital
01/13/20 Stifel
Amarin should rally on failure of two potential competitors, says Stifel
01/13/20 B. Riley FBR
Acasti Pharma downgraded to Neutral from Buy at B. Riley FBR
ACST Acasti Pharma
$0.53 /

+0.0158 (+3.05%)

ACST Acasti Pharma
$0.53 /

+0.0158 (+3.05%)

Hot Stocks
Precision BioSciences regains rights to in vivo HBV program » 07:11
07/06/20
07/06
07:11
07/06/20
07:11
DTIL

Precision BioSciences

$8.44 /

+0.06 (+0.72%)

, GILD

Gilead

$76.31 /

+0.28 (+0.37%)

Precision BioSciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
GILD Gilead
$76.31 /

+0.28 (+0.37%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

Recommendations
Broadcom price target raised to $322 from $286 at Goldman Sachs » 07:11
07/06/20
07/06
07:11
07/06/20
07:11
AVGO

Broadcom

$315.33 /

+2.62 (+0.84%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AVGO Broadcom
$315.33 /

+2.62 (+0.84%)

AVGO Broadcom
$315.33 /

+2.62 (+0.84%)

06/26/20
Fly Intel: Top five analyst upgrades
06/26/20 Evercore ISI
Evercore upgrades Broadcom to Outperform, sees Apple sales driving upside
06/26/20 Evercore ISI
Broadcom upgraded to Outperform from In Line at Evercore ISI
06/22/20 Mizuho
Broadcom price target raised to $350 from $325 at Mizuho
AVGO Broadcom
$315.33 /

+2.62 (+0.84%)

AVGO Broadcom
$315.33 /

+2.62 (+0.84%)

AVGO Broadcom
$315.33 /

+2.62 (+0.84%)

AVGO Broadcom
$315.33 /

+2.62 (+0.84%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.